Silexion Therapeutics Corp

NASDAQ:SLXNUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Contact Information

Headquarters

12 Abba Hillel RoadRAMAT GAN, NY, Israel 5250606

Phone

---

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Ilan Hadar

Chief Financial Officer

Mirit Hadar

Chief Scientific and Development Officer

Mitchell Shirvan

Director

Ilan Levin

Independent Director

Dror Abramov